vs
亚盛医药集团（AAPG）与RBB Bancorp（RBB）财务数据对比。点击上方公司名可切换其他公司
亚盛医药集团的季度营收约是RBB Bancorp的1.0倍（$32.6M vs $32.3M）
亚盛医药集团是一家全球性临床阶段生物技术企业，专注于开发用于治疗癌症、慢性病毒感染及衰老相关疾病的创新靶向药物，核心研发方向为靶向细胞凋亡通路的小分子药物，业务覆盖中、美等全球市场，致力于满足未被满足的临床需求。
RBB银行控股公司是总部位于美国的金融控股集团，旗下核心主体为皇家商业银行，主要服务亚裔社群、中小微企业、不动产投资者及零售客户，提供商业信贷、储蓄存款、财富管理等多元金融服务，业务覆盖美国沿海核心都会区。
AAPG vs RBB — 直观对比
营收规模更大
AAPG
是对方的1.0倍
$32.3M
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $32.6M | $32.3M |
| 净利润 | $11.4M | $10.2M |
| 毛利率 | 90.7% | — |
| 营业利润率 | — | 39.5% |
| 净利率 | — | 31.5% |
| 营收同比 | — | 12.6% |
| 净利润同比 | — | 132.1% |
| 每股收益（稀释后） | — | $0.59 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AAPGRBB
| Q4 25 | — | $32.3M | ||
| Q3 25 | — | $32.6M | ||
| Q2 25 | $32.6M | $35.8M | ||
| Q1 25 | — | $28.5M | ||
| Q4 24 | — | $28.7M | ||
| Q3 24 | — | $30.3M | ||
| Q2 24 | — | $27.5M | ||
| Q1 24 | — | $28.2M |
净利润AAPGRBB
| Q4 25 | — | $10.2M | ||
| Q3 25 | — | $10.1M | ||
| Q2 25 | $11.4M | $9.3M | ||
| Q1 25 | — | $2.3M | ||
| Q4 24 | — | $4.4M | ||
| Q3 24 | — | $7.0M | ||
| Q2 24 | — | $7.2M | ||
| Q1 24 | — | $8.0M |
毛利率AAPGRBB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 90.7% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率AAPGRBB
| Q4 25 | — | 39.5% | ||
| Q3 25 | — | 40.7% | ||
| Q2 25 | — | 36.1% | ||
| Q1 25 | — | 11.2% | ||
| Q4 24 | — | 17.6% | ||
| Q3 24 | — | 31.6% | ||
| Q2 24 | — | 35.6% | ||
| Q1 24 | — | 39.9% |
净利率AAPGRBB
| Q4 25 | — | 31.5% | ||
| Q3 25 | — | 31.2% | ||
| Q2 25 | — | 26.1% | ||
| Q1 25 | — | 8.0% | ||
| Q4 24 | — | 15.3% | ||
| Q3 24 | — | 23.1% | ||
| Q2 24 | — | 26.4% | ||
| Q1 24 | — | 28.4% |
每股收益（稀释后）AAPGRBB
| Q4 25 | — | $0.59 | ||
| Q3 25 | — | $0.59 | ||
| Q2 25 | — | $0.52 | ||
| Q1 25 | — | $0.13 | ||
| Q4 24 | — | $0.26 | ||
| Q3 24 | — | $0.39 | ||
| Q2 24 | — | $0.39 | ||
| Q1 24 | — | $0.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $212.3M |
| 总债务越低越好 | — | $119.9M |
| 股东权益账面价值 | — | $523.4M |
| 总资产 | — | $4.2B |
| 负债/权益比越低杠杆越低 | — | 0.23× |
8季度趋势，按日历期对齐
现金及短期投资AAPGRBB
| Q4 25 | — | $212.3M | ||
| Q3 25 | — | $234.9M | ||
| Q2 25 | — | $191.9M | ||
| Q1 25 | — | $238.8M | ||
| Q4 24 | — | $257.7M | ||
| Q3 24 | — | $349.4M | ||
| Q2 24 | — | $252.8M | ||
| Q1 24 | — | — |
总债务AAPGRBB
| Q4 25 | — | $119.9M | ||
| Q3 25 | — | $119.8M | ||
| Q2 25 | — | $119.7M | ||
| Q1 25 | — | $119.6M | ||
| Q4 24 | — | $119.5M | ||
| Q3 24 | — | $119.4M | ||
| Q2 24 | — | $119.3M | ||
| Q1 24 | — | $119.2M |
股东权益AAPGRBB
| Q4 25 | — | $523.4M | ||
| Q3 25 | — | $514.3M | ||
| Q2 25 | — | $517.7M | ||
| Q1 25 | — | $510.3M | ||
| Q4 24 | — | $507.9M | ||
| Q3 24 | — | $509.7M | ||
| Q2 24 | — | $511.3M | ||
| Q1 24 | — | $514.0M |
总资产AAPGRBB
| Q4 25 | — | $4.2B | ||
| Q3 25 | — | $4.2B | ||
| Q2 25 | — | $4.1B | ||
| Q1 25 | — | $4.0B | ||
| Q4 24 | — | $4.0B | ||
| Q3 24 | — | $4.0B | ||
| Q2 24 | — | $3.9B | ||
| Q1 24 | — | $3.9B |
负债/权益比AAPGRBB
| Q4 25 | — | 0.23× | ||
| Q3 25 | — | 0.23× | ||
| Q2 25 | — | 0.23× | ||
| Q1 25 | — | 0.23× | ||
| Q4 24 | — | 0.24× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.23× | ||
| Q1 24 | — | 0.23× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $43.4M |
| 自由现金流经营现金流 - 资本支出 | — | $42.6M |
| 自由现金流率自由现金流/营收 | — | 131.8% |
| 资本支出强度资本支出/营收 | — | 2.5% |
| 现金转化率经营现金流/净利润 | — | 4.26× |
| 过去12个月自由现金流最近4个季度 | — | $73.5M |
8季度趋势，按日历期对齐
经营现金流AAPGRBB
| Q4 25 | — | $43.4M | ||
| Q3 25 | — | $2.1M | ||
| Q2 25 | — | $21.7M | ||
| Q1 25 | — | $7.8M | ||
| Q4 24 | — | $58.5M | ||
| Q3 24 | — | $24.5M | ||
| Q2 24 | — | $11.7M | ||
| Q1 24 | — | $4.8M |
自由现金流AAPGRBB
| Q4 25 | — | $42.6M | ||
| Q3 25 | — | $1.8M | ||
| Q2 25 | — | $21.6M | ||
| Q1 25 | — | $7.6M | ||
| Q4 24 | — | $57.7M | ||
| Q3 24 | — | $24.2M | ||
| Q2 24 | — | $11.5M | ||
| Q1 24 | — | $4.7M |
自由现金流率AAPGRBB
| Q4 25 | — | 131.8% | ||
| Q3 25 | — | 5.4% | ||
| Q2 25 | — | 60.2% | ||
| Q1 25 | — | 26.7% | ||
| Q4 24 | — | 201.0% | ||
| Q3 24 | — | 80.0% | ||
| Q2 24 | — | 42.0% | ||
| Q1 24 | — | 16.6% |
资本支出强度AAPGRBB
| Q4 25 | — | 2.5% | ||
| Q3 25 | — | 1.1% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 0.6% | ||
| Q4 24 | — | 2.7% | ||
| Q3 24 | — | 0.8% | ||
| Q2 24 | — | 0.5% | ||
| Q1 24 | — | 0.5% |
现金转化率AAPGRBB
| Q4 25 | — | 4.26× | ||
| Q3 25 | — | 0.21× | ||
| Q2 25 | — | 2.32× | ||
| Q1 25 | — | 3.39× | ||
| Q4 24 | — | 13.34× | ||
| Q3 24 | — | 3.50× | ||
| Q2 24 | — | 1.61× | ||
| Q1 24 | — | 0.60× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AAPG
| Products | $29.7M | 91% |
| Others | $2.9M | 9% |
RBB
暂无分部数据
